Bevacizumab in combination with biweekly capecitabine and irinotecan as first-line treatment for patients with metastatic colorectal cancer

摘要

Background: Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC). The aim of this study was to evaluate the efficacy and safety of this regimen in combination with bevacizumab (BV), as first-line treatment for mCRC.